APIRx is a pioneering pharmaceutical company based in New York, NY, specializing in the production of cannabinoid active pharmaceutical ingredients (APIs) and drug products derived from natural extracts of the cannabis sativa plant. Their groundbreaking end-to-end cGMP process ensures the creation of pure and unaltered cannabinoids, leading to the development of safer and more effective cannabinoid-based medicines and products.
With a mission to provide natural and regulatory-compliant solutions for various therapeutic applications, APIRx aims to address chronic pain, wound healing, dermatological diseases, medication-related osteonecrosis of the jaws (MRONJ), appetite control, and more. Their state-of-the-art technologies and commitment to environmental friendliness position them as a leading player in the emerging cannabis industry, which is projected to reach $12 billion by 2025 in the U.S. medical market alone.
Generated from the website
